Last updated: 11/04/2018 13:50:17

Efficacy of potassium nitrate solution in reducing dentinal hypersensitivity

GSK study ID
Z3770633
Clinicaltrials.gov ID
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Completed
Completed
Overview
Eligibility
Locations
Study documents
Results summary
Plain language summaries
Additional information

Trial overview

Official title: A proof of principle study investigating the effects of a potassium nitrate solution in reducing dentinal hypersensitivity
Trial description: An exploratory study investigating the direct application of potassium nitrate (KNO3) solutions of different concentrations in reducing dentine hypersensitivity.
Primary purpose:
Treatment
Trial design:
Parallel Assignment
Masking:
Double (Participant, Investigator)
Allocation:
Randomized
Primary outcomes:

Between treatment comparison of the adjusted mean change from baseline of response to evaporative (air) stimuli immediately following treatment on Day 5 using a Visual Analog Scale (VAS) in 5% potassium nitrate solution and 2.5% potassium nitrate solution

Timeframe: Baseline and immediately after treatment on Day 5

Secondary outcomes:

Between treatment comparison of the adjusted mean change from baseline of response to evaporative (air) stimuli immediately following treatment on Day 1 using a VAS

Timeframe: Baseline and immediately after treatment on Day 1

Between treatment comparison of the adjusted mean change from baseline of response to evaporative (air) stimuli at 10 mins post treatment on Day 1 using a VAS

Timeframe: Baseline and 10 mins post treatment on Day 1

Between treatment comparison of the adjusted mean change from baseline of response to evaporative (air) stimuli at 20 mins post treatment on Day 1 using a VAS.

Timeframe: Baseline and 20 mins post treatment on Day 1

Between treatment comparison of the adjusted mean change from baseline of response to evaporative (air) stimuli following treatment on Day 2 using a VAS

Timeframe: Baseline and immediately after treatment on Day 2

Between treatment comparison of the adjusted mean change from baseline of response to evaporative (air) stimuli at 10 mins post treatment on Day 2 using a VAS

Timeframe: Baseline and 10 mins post treatment on Day 2

Between treatment comparison of the adjusted mean change from baseline of response to evaporative (air) stimuli at 20 mins post treatment on Day 2 using a VAS

Timeframe: Baseline and 20 mins post treatment on Day 2

Between treatment comparison of the adjusted mean change from baseline of response to evaporative (air) stimuli immediately following treatment on Day 3 using a VAS

Timeframe: Baseline and immediately after treatment on Day 3

Between treatment comparison of the adjusted mean change from baseline of response to evaporative (air) stimuli at 10 mins post treatment on Day 3 using a VAS

Timeframe: Baseline and 10 mins post treatment on Day 3

Between treatment comparison of the adjusted mean change from baseline of response to evaporative (air) stimuli at 20 mins post treatment on Day 3 using a VAS

Timeframe: Baseline and 20 mins post treatment on Day 3

Between treatment comparison of the adjusted mean change from baseline of response to evaporative (air) stimuli following treatment on Day 4 using a VAS

Timeframe: Baseline and immediately after treatment on Day 4

Between treatment comparison of the adjusted mean change from baseline of response to evaporative (air) stimuli at 10 mins post treatment on Day 4 using a VAS

Timeframe: Baseline and 10 mins post treatment on Day 4

Between treatment comparison of the adjusted mean change from baseline of response to evaporative (air) stimuli 20 mins post treatment on Day 4 using a VAS

Timeframe: Baseline and 20 mins post treatment on Day 4

Between treatment comparison of the adjusted mean change from baseline of response to evaporative (air) stimuli immediately following treatment on Day 5 using a VAS in 5% potassium nitrate solution and water; 2.5% potassiun nitrate solution and water

Timeframe: Baseline and immediately after treatment on Day 5

Between treatment comparison of the adjusted mean change from baseline of response to evaporative (air) stimuli at 10 mins post treatment on Day 5 using a VAS

Timeframe: Baseline and 10 mins post treatment on Day 5

Between treatment comparison of the adjusted mean change from baseline of response to evaporative (air) stimuli at 20 mins post treatment on Day 5 using a VAS

Timeframe: Baseline and 20 mins post treatment on Day 5

Interventions:
Drug: 5% Potassium nitrate
Drug: 2.5% Potassium nitrate
Other: Sterile water
Enrollment:
32
Observational study model:
Not applicable
Primary completion date:
2009-31-10
Time perspective:
Not applicable
Clinical publications:
Not applicable
Medical condition
Dentine Hypersensitivity
Product
potassium nitrate
Collaborators
Not applicable
Study date(s)
September 2009 to October 2009
Type
Interventional
Phase
2

Participation criteria

Sex
Female & Male
Age
18 - 65 years
Accepts healthy volunteers
No
  • Self-reported history of dentinal hypersensitivity lasting more than 6 months and a primary complaint of sensitive teeth
  • Three teeth that can be isolated that meet all of the following criteria at the screening visit:
  • Chronic disease or other condition that is associated with intermittent episodes of constant daily pain, such as arthritis, low back pain, etc.
  • An condition or medication that causes xerostomia as determined by investigator

Trial location(s)

Location
Status
Contact us
Contact us
Location
University Park Research Center (UPRC)
Fort Wayne, IN, United States, 46825
Status
Study Complete

Study documents

Scientific result summary
Available language(s): English

If you wish to request for full study report, please contact - [email protected]

Results overview

Results posted on ClinicalTrials.gov

Recruitment status
Completed
Actual primary completion date
2009-31-10
Actual study completion date
2009-31-10

Plain language summaries

Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.

Additional information about the trial

Additional information
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website